Divalproex Sodium Tablet, Delayed Release
NDC Package 57237-047-01
Package Information
Divalproex Sodium tablets is a medication used to treat seizure disorders, certain psychiatric conditions (manic phase of bipolar disorder), and to prevent migraine headaches. This formulation utilizes a tablet, delayed release delivery system. Marketed by Rising Pharma Holdings, Inc., this product is identified by NDC 57237-047 and is authorized under FDA application ANDA090554.
Identification & Billing
- RxCUI: 1099625 - divalproex sodium 125 MG Delayed Release Oral Tablet
- RxCUI: 1099678 - divalproex sodium 250 MG Delayed Release Oral Tablet
- RxCUI: 1099870 - divalproex sodium 500 MG Delayed Release Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 57237 - Rising Pharma Holdings, Inc.
- 57237-047 - Divalproex Sodium
- 57237-047-01 - 100 TABLET, DELAYED RELEASE in 1 BOTTLE
- 57237-047 - Divalproex Sodium
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (57237-047). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 57237-047-01 identifies a specific commercial package of 100 tablet, delayed release in 1 bottle of Divalproex Sodium, a human prescription drug labeled by Rising Pharma Holdings, Inc.. This tablet, delayed release is formulated for oral use and contains divalproex sodium as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Rising Pharma Holdings, Inc. on October 24, 2014. The current certification is valid through December 31, 2027.
What are the primary indications for this medication?
This medication is used to treat seizure disorders, certain psychiatric conditions (manic phase of bipolar disorder), and to prevent migraine headaches. It works by restoring the balance of certain natural substances (neurotransmitters) in the brain.
How is this Rising Pharma Holdings, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 57237004701. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 100 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.